The effects of adipose tissue-derived mesenchymal STEM cell treatment on some hematological and biochemical parameters and sdma levels in cats with chronic renal failure

The lifespan of cats has been prolonged regarding the domestication process. However, the prevalence of chronic diseases also increases with age. Chronic kidney disease (CKD) is more prevalent among the elderly cat population. Symptomatic and palliative treatments have been implemented due to manage life quality. In recent years, adipose-derived mesenchymal stem cells (ADMSCs) have been used as a supportive treatment because of their anti-inflammatory activities. Thus, we aimed to evaluate some clinical laboratory parameters of the ADMSCs treated cats suffering from CKD. Subsequent to general examination, six mixed breeds, sterile, male, 4 to 17 years old cats diagnosed with chronic kidney disease were treated with ADMSCs besides conventional therapy with the informed consent of the patient's owner. The allogenic 1x106 cells per kg ADMSCs were administered (CellPro+, MarStem Cell Tech., Istanbul) by the intravenous route 14 days intervals two times. The total blood and sera were collected before and 24 hours after the treatments and evaluated the red blood cells (RBC), blood urea nitrogen (BUN) and creatine (Crea) levels to screen the efficiency. Whilst the RBC levels were increased (p<0.05), BUN and Crea levels were decreased (p<0.05) end of the treatments. The well-being of general conditions after ADMSCs therapy overall the cats was observed. To date, there is still no consensus on stem cell therapies for CKDs. In this study, we concluded that ADMSCs have beneficial effects as add-on therapy to manage CKDs in cats. Although, need to conduct long-term monitoring in clinical trials for standardization.